Covered recipient · General Payments record
JOHN SLATTERY
General Payments · PY2024
$588.71
- Reported across 17 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $588.71 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $274.43 | 8 |
| GlaxoSmithKline, LLC. | $110.72 | 1 |
| Alvogen Inc | $75.72 | 3 |
| Mallinckrodt Hospital Products Inc. | $58.42 | 2 |
| Kiniksa Pharmaceuticals International, plc | $53.83 | 2 |
| ANI Pharmaceuticals, Inc. | $15.59 | 1 |
By program year
All program years on this page · sorted by year
| Program year | Amount | Records |
|---|---|---|
| PY2024 | $588.71 | 17 |
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
Program year 2024
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alvogen Inc | $24.77 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137625745 | CMS |
| Alvogen Inc | $26.18 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137625749 | CMS |
| Alvogen Inc | $24.77 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137625754 | CMS |
| ANI Pharmaceuticals, Inc. | $15.59 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1091150534 | CMS |
| GlaxoSmithKline, LLC. | $110.72 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116329428 | CMS |
| Kiniksa Pharmaceuticals International, plc | $26.99 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154874148 | CMS |
| Kiniksa Pharmaceuticals International, plc | $26.84 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154874190 | CMS |
| Mallinckrodt Hospital Products Inc. | $26.00 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145139489 | CMS |
| Mallinckrodt Hospital Products Inc. | $32.42 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145139494 | CMS |
| UCB, Inc. | $15.23 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158634 | CMS |
| UCB, Inc. | $23.84 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158636 | CMS |
| UCB, Inc. | $35.35 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158638 | CMS |
| UCB, Inc. | $22.44 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158640 | CMS |
| UCB, Inc. | $122.55 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158642 | CMS |
| UCB, Inc. | $19.11 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158644 | CMS |
| UCB, Inc. | $21.42 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158646 | CMS |
| UCB, Inc. | $14.49 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143158648 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2024
- Source files
- Dataset page · Bulk file · PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.